Neuroblastoma Origin and Therapeutic Targets for Immunotherapy
Neuroblastoma is a pediatric solid cancer of heterogeneous clinical behavior. The unique features of this type of cancer frequently hamper the process of determining clinical presentation and predicting therapy effectiveness. The tumor can spontaneously regress without treatment or actively develop...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2018/7394268 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849408754443878400 |
|---|---|
| author | Irina V. Kholodenko Daniel V. Kalinovsky Igor I. Doronin Sergey M. Deyev Roman V. Kholodenko |
| author_facet | Irina V. Kholodenko Daniel V. Kalinovsky Igor I. Doronin Sergey M. Deyev Roman V. Kholodenko |
| author_sort | Irina V. Kholodenko |
| collection | DOAJ |
| description | Neuroblastoma is a pediatric solid cancer of heterogeneous clinical behavior. The unique features of this type of cancer frequently hamper the process of determining clinical presentation and predicting therapy effectiveness. The tumor can spontaneously regress without treatment or actively develop and give rise to metastases despite aggressive multimodal therapy. In recent years, immunotherapy has become one of the most promising approaches to the treatment of neuroblastoma. Still, only one drug for targeted immunotherapy of neuroblastoma, chimeric monoclonal GD2-specific antibodies, is used in the clinic today, and its application has significant limitations. In this regard, the development of effective and safe GD2-targeted immunotherapies and analysis of other potential molecular targets for the treatment of neuroblastoma represents an important and topical task. The review summarizes biological characteristics of the origin and development of neuroblastoma and outlines molecular markers of neuroblastoma and modern immunotherapy approaches directed towards these markers. |
| format | Article |
| id | doaj-art-7a878fbc68be4d47be4cc03930ac72ef |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-7a878fbc68be4d47be4cc03930ac72ef2025-08-20T03:35:41ZengWileyJournal of Immunology Research2314-88612314-71562018-01-01201810.1155/2018/73942687394268Neuroblastoma Origin and Therapeutic Targets for ImmunotherapyIrina V. Kholodenko0Daniel V. Kalinovsky1Igor I. Doronin2Sergey M. Deyev3Roman V. Kholodenko4Orekhovich Institute of Biomedical Chemistry, 10 Pogodinskaya St., Moscow 119121, RussiaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 16/10 Miklukho-Maklaya St., Moscow 117997, RussiaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 16/10 Miklukho-Maklaya St., Moscow 117997, RussiaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 16/10 Miklukho-Maklaya St., Moscow 117997, RussiaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 16/10 Miklukho-Maklaya St., Moscow 117997, RussiaNeuroblastoma is a pediatric solid cancer of heterogeneous clinical behavior. The unique features of this type of cancer frequently hamper the process of determining clinical presentation and predicting therapy effectiveness. The tumor can spontaneously regress without treatment or actively develop and give rise to metastases despite aggressive multimodal therapy. In recent years, immunotherapy has become one of the most promising approaches to the treatment of neuroblastoma. Still, only one drug for targeted immunotherapy of neuroblastoma, chimeric monoclonal GD2-specific antibodies, is used in the clinic today, and its application has significant limitations. In this regard, the development of effective and safe GD2-targeted immunotherapies and analysis of other potential molecular targets for the treatment of neuroblastoma represents an important and topical task. The review summarizes biological characteristics of the origin and development of neuroblastoma and outlines molecular markers of neuroblastoma and modern immunotherapy approaches directed towards these markers.http://dx.doi.org/10.1155/2018/7394268 |
| spellingShingle | Irina V. Kholodenko Daniel V. Kalinovsky Igor I. Doronin Sergey M. Deyev Roman V. Kholodenko Neuroblastoma Origin and Therapeutic Targets for Immunotherapy Journal of Immunology Research |
| title | Neuroblastoma Origin and Therapeutic Targets for Immunotherapy |
| title_full | Neuroblastoma Origin and Therapeutic Targets for Immunotherapy |
| title_fullStr | Neuroblastoma Origin and Therapeutic Targets for Immunotherapy |
| title_full_unstemmed | Neuroblastoma Origin and Therapeutic Targets for Immunotherapy |
| title_short | Neuroblastoma Origin and Therapeutic Targets for Immunotherapy |
| title_sort | neuroblastoma origin and therapeutic targets for immunotherapy |
| url | http://dx.doi.org/10.1155/2018/7394268 |
| work_keys_str_mv | AT irinavkholodenko neuroblastomaoriginandtherapeutictargetsforimmunotherapy AT danielvkalinovsky neuroblastomaoriginandtherapeutictargetsforimmunotherapy AT igoridoronin neuroblastomaoriginandtherapeutictargetsforimmunotherapy AT sergeymdeyev neuroblastomaoriginandtherapeutictargetsforimmunotherapy AT romanvkholodenko neuroblastomaoriginandtherapeutictargetsforimmunotherapy |